Philip Morris in talks with Lexaria Bioscience Corp to license their proprietary Nicotine infusion technology. This technology enables higher bioavailability rates for Nicotin and other molecules than is possible without lipophilic enhancement technology – allowing for lower overall dosing requirements and/or higher effectiveness in active molecule delivery. The Company hopes to reduce other common but less healthy ingestion methods such as smoking as it embraces the benefits of public health.